The standard cholesterol test that millions of Americans receive each year, the LDL cholesterol (LDL-C) measurement, may not be the best tool for deciding who should take statins. A simulation study published April 8 in JAMA compared three different blood tests for guiding lipid-lowering therapy in primary prevention and concluded that the apolipoprotein B (apoB) test outperforms both LDL-C and non-HDL-C at a cost-effective price.
The finding has direct implications for clinical practice, and for the millions of patients who are started on or withheld from statin therapy based on their LDL cholesterol numbers.
The Three Tests
Standard lipid panels measure LDL cholesterol, the mass of cholesterol carried inside low-density lipoprotein particles. Non-HDL cholesterol adds in the cholesterol carried by other atherogenic particles (VLDL, IDL). ApoB takes a different approach: it directly counts every atherogenic particle in the blood, because each such particle, whether LDL, IDL, or VLDL, carries exactly one apoB molecule.
The difference matters because individuals can have normal LDL cholesterol but high particle numbers, or vice versa. A patient whose LDL particles are cholesterol-poor might show a normal LDL-C value while having many more particles than someone with cholesterol-rich LDL at the same LDL-C level. Those extra particles increase cardiovascular risk in ways that LDL-C measurement can miss.
The Simulation
Led by Ciaran Kohli-Lynch and colleagues at Northwestern University Feinberg School of Medicine, the team used data from the National Health and Nutrition Examination Survey (NHANES, 2005-2016) to construct a simulated cohort of 250,000 US adults eligible for primary prevention statin therapy but free of established cardiovascular disease.
They compared three strategies:
- Treat to an LDL-C goal below 100 mg/dL
- Treat to a non-HDL-C goal below 118 mg/dL
- Treat to an apoB goal below 78.7 mg/dL
In all strategies, patients whose initial statin did not achieve the goal were escalated to a higher-intensity statin, then to add-on ezetimibe if still above goal.
Results
The apoB-guided strategy produced the largest reduction in heart attacks and strokes and the largest gain in population health. Compared to the non-HDL-C strategy, targeting apoB gained an additional 1,324 quality-adjusted life years (QALYs) across the simulated population at an incremental cost of $40.2 million, producing an incremental cost-effectiveness ratio (ICER) of $30,300 per QALY.
The standard threshold for cost-effectiveness in the United States is $120,000 per QALY. At that threshold, the apoB strategy was optimal in 65 percent of probabilistic sensitivity analyses, with non-HDL-C optimal in 25 percent.
The non-HDL-C strategy, in turn, dominated LDL-C: it was both less expensive and more effective than targeting standard LDL cholesterol, saving $2.1 million across the population while gaining 965 QALYs.
Why This Matters for Clinicians
LDL cholesterol measurement is inexpensive, typically included in a standard lipid panel costing $10 to $30. ApoB testing is more expensive, usually $20 to $60. The higher absolute cost of the apoB strategy in the simulation reflects not the assay itself but the longer life expectancy and prolonged treatment duration in patients whose cardiovascular risk is better identified and managed.
The argument for switching to apoB rests on the premise that what matters for atherosclerosis is the number of atherogenic particles, not the mass of cholesterol they carry. This is not a new scientific insight, the lipidology community has debated it for years. What the JAMA study adds is a cost-effectiveness analysis specific to primary prevention in the US healthcare system, using contemporary drug pricing.
Caveats
This is a computer simulation, not a randomized trial. The model assumes that treating to lower apoB levels translates to proportional risk reduction, which is supported by trial data but has not been specifically tested in a trial comparing apoB-guided vs LDL-C-guided therapy head-to-head.
The simulation also uses cost data that may not reflect all clinical settings. The ICER of $30,300 per QALY is favorable by US standards, but the incremental cost of apoB testing, and whether insurers would cover it, remains a practical barrier.
The study was funded by an American Heart Association Career Development Award (24CDA1274989) and led by Kohli-Lynch, with co-authors including Samuel Luebbe, Allan D. Sniderman (McGill University), Andrew E. Moran (Columbia University), and John T. Wilkins (Northwestern).
Disclosure: Based on a peer-reviewed paper in JAMA, published online April 8, 2026. DOI: 10.1001/jama.2026.2986. Reported via ScienceDaily (July 6, 2026) and Northwestern Now (April 8, 2026).